PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES

• Constantine Tam,
• Mazyar Shadman,
• Jeff Sharman,
• Gavin Cull,
• Tycel Phillips,
• Judith Trotman,
• Aileen Cohen,
• Heather Allewelt,
• Rocco Crescenzo,
• Richard Delarue,
• Heather Zhang,
• Bilal Tariq,
• Sri Sahasranaman,
• Ying C Ou,
• Ian W Flinn

Affiliations

Constantine Tam

1 Alfred Health and Monash University, Melbourne, Australia

Mazyar Shadman

2 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, United States

Jeff Sharman

3 Willamette Valley Cancer Institute and Research Center, Eugene, United States

Gavin Cull

4 Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia

Tycel Phillips

5 Hematology Clinic, Rogel Cancer Center, University of Michigan Health System, Ann Arbor, United States

Judith Trotman

6 Concord Repatriation General Hospital, University of Sydney, Concord, Australia

Aileen Cohen

7 BeiGene USA, Inc., San Mateo, United States

Heather Allewelt

7 BeiGene USA, Inc., San Mateo, United States

Rocco Crescenzo

7 BeiGene USA, Inc., San Mateo, United States

Richard Delarue

7 BeiGene USA, Inc., San Mateo, United States

Heather Zhang

7 BeiGene USA, Inc., San Mateo, United States

Bilal Tariq

7 BeiGene USA, Inc., San Mateo, United States

Sri Sahasranaman

7 BeiGene USA, Inc., San Mateo, United States

Ying C Ou

7 BeiGene USA, Inc., San Mateo, United States

Ian W Flinn

8 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, United States